ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…
Insights into Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Recent research found inflammatory arthritis caused by immune checkpoint inhibitors (ICIs) may become a long-term disease, requiring rheumatology care and immunomodulatory treatment. Some patients experience active inflammatory arthritis years after ICI cessation…
Denosumab Dosing Delays Tied to Increased Fracture Risk
NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
How to Empower Lupus Patients Through Social Media & Online Resources
Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…
RheumPAC Supports Rheumatology Through the Pandemic
With usual in-person fundraisers and meetings not possible during the pandemic, RheumPAC is finding creative ways to keep advocating for influential legislation and ensure rheumatology’s voice is heard in Washington, D.C.
State Rheumatology Societies Adjust Meeting Schedules, Formats in Response to COVID-19
Many in-person meetings have been canceled, postponed or moved to virtual formats, likely with lasting economic impacts on state societies.
COVID-19: Practical Tips for Practices
The ACR’s July 13 online town hall, “COVID-19 Guidance for Community Practices,” covered telehealth, safe clinic reopening and Department of Health & Human Services loans.
Doctors Detail Kawasaki-Like Disease in Adult COVID-19 Patients
(Reuters Health)—During the COVID-19 pandemic, an inflammatory condition similar to Kawasaki disease has been reported in children and adolescents, and now two groups of New York doctors each describe a case, one in a 36-year-old woman and one in a 45-year-old man.1 “We’re still learning how COVID-19 is affecting children and adults. The better we…
FDA Approves Tremfya (Guselkumab) for Adult Patients with Psoriatic Arthritis
HORSHAM, PA—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.1,2 Tremfya is the first treatment approved for active PsA that selectively inhibits interleukin (IL)…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 332
- Next Page »